Improvement in health‐related quality of life and symptoms of anxiety and depression in patients with alopecia areata randomized to baricitinib or placebo: Results from two international randomized controlled trials
Piraccini B, Ohyama M, Craiglow B, Bewley A, Ding Y, Chen Y, Dutronc Y, Pierce E, Durand F, Mostaghimi A. Improvement in health‐related quality of life and symptoms of anxiety and depression in patients with alopecia areata randomized to baricitinib or placebo: Results from two international randomized controlled trials. JEADV Clinical Practice 2023, 3: 242-248. DOI: 10.1002/jvc2.269.Peer-Reviewed Original ResearchSevere alopecia areataSymptoms of anxietyHealth-related qualityAlopecia areataWeek 36Hair regrowthAutoimmune hair loss disorderPsychological burdenBackground Alopecia areataProportion of patientsPhase 3 trialSelective Janus kinase 1JAK-2 inhibitorHair loss disorderBaricitinib 2Nonresponder imputationMethods PatientsHADS scoresMore patientsLarge trialsHospital AnxietyDepression ScaleAA symptomsPsychosocial distressAnalysis of covarianceThe Invisible Impact of a Visible Disease: Psychosocial Impact of Alopecia Areata
Mesinkovska N, Craiglow B, Ball S, Morrow P, Smith S, Pierce E, Shapiro J. The Invisible Impact of a Visible Disease: Psychosocial Impact of Alopecia Areata. Dermatology And Therapy 2023, 13: 1503-1515. PMID: 37289409, PMCID: PMC10307747, DOI: 10.1007/s13555-023-00941-z.Peer-Reviewed Original ResearchPsychological impactEmotional burdenNegative psychological impactGreater psychological impactPoor QoLPsychosocial impactAA symptomsSocial consequencesIllness impactParticipantsIllness characteristicsAnalysis of varianceNational Alopecia Areata FoundationConclusionsThese resultsStigmaQuality of lifeSeverity subgroupsAnxietyOutcome measuresPhysical impactScalp hair lossDepressionQoLAlopecia areataCross-sectional study